Ares Life Sciences has agreed to buy 45.6% of listed French biopharma Stallergenes from Wendel, and plans to file a mandatory takeover offer for all the remaining shares.
Asset manager plans expansion into PE GP-leds, bolstering its existing real estate secondaries strategy
Sale to Australian travel agency Flight Centre marks the 13th exit for the GP’s 2010 buyout fund
UK small-cap sponsor could return to market for its next GBP 125m fund at the end of 2023
France-headquartered GP stakes investor is seeking to support sponsors as they become multi-strategy managers, co-founder Dominique Gaillard tells Unquote